RAS mutation frequency within selected cytogenetic subgroups of AML patients for whom cytogenetic data were available (n = 922)
. | NRAS . | . | . | KRAS . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cytogenetic subgroup . | Mutant, no. (%) . | Nonmutant, no. (%) . | P . | Mutant, no. (%) . | Nonmutant, no. (%) . | P . | ||||
| No data | 17 | 167 | .3 | 8 | 131 | .8 | ||||
| Cytogenetics available | 109 | 813 | 31 | 569 | ||||||
| Favorable | ||||||||||
| t(15; 17) | 8 (7) | 138 (17) | .008* | 5 (16) | 109 (19) | .8 | ||||
| t(8; 21) | 5 (5) | 82 (10) | .07 | 3 (10) | 56 (10) | > .99 | ||||
| inv(16) | 11 (10) | 49 (6) | .14 | 7 (23) | 35 (6) | .004† | ||||
| Intermediate | ||||||||||
| Normal | 48 (44) | 292 (36) | .11 | 7 (23) | 191 (34) | .2 | ||||
| abn(11q) | 1 (1) | 11 (1) | > .99 | 1 (3) | 8 (1) | .3 | ||||
| abn(12p) | 1 (1) | 11 (1) | > .99 | 1 (3) | 7 (1) | .3 | ||||
| abn(15q) | 1 (1) | 5 (1) | .5 | 0 (0) | 5 (1) | > .99 | ||||
| abn(16q) | 1 (1) | 17 (2) | .7 | 2 (6) | 11 (2) | .14 | ||||
| abn(17p) | 1 (1) | 18 (2) | .7 | 0 (0) | 12 (2) | > .99 | ||||
| abn(1p) | 1 (1) | 14 (2) | > .99 | 1 (3) | 6 (1) | .3 | ||||
| abn(1q) | 2 (2) | 9 (1) | .6 | 1 (3) | 7 (1) | .3 | ||||
| abn(20q) | 0 (0) | 8 (1) | .6 | 0 (0) | 8 (1) | > .99 | ||||
| abn(21q) | 0 (0) | 8 (1) | .6 | 1 (3) | 3 (1) | .2 | ||||
| abn(6q) | 0 (0) | 9 (1) | .6 | 0 (0) | 5 (1) | > .99 | ||||
| abn(7p) | 1 (1) | 14 (2) | > .99 | 0 (0) | 10 (2) | > .99 | ||||
| add(5q) | 0 (0) | 5 (1) | > .99 | 0 (0) | 5 (1) | > .99 | ||||
| add(7q) | 0 (0) | 7 (1) | > .99 | 1 (3) | 6 (1) | .3 | ||||
| del(13q) | 0 (0) | 5 (1) | > .99 | 0 (0) | 2 (< 0.5) | > .99 | ||||
| del(7q) | 2 (2) | 23 (3) | .8 | 1 (3) | 19 (3) | > .99 | ||||
| del(9q) | 0 (0) | 18 (2) | .2 | 0 (0) | 10 (2) | > .99 | ||||
| i(8q) | 0 (0) | 3 (< 0.5) | > .99 | 0 (0) | 2 (< 0.5) | > .99 | ||||
| −3 | 0 (0) | 5 (1) | > .99 | 0 (0) | 5 (1) | > .99 | ||||
| −9 | 1 (1) | 2 (< 0.5) | .3 | 0 (0) | 3 (1) | > .99 | ||||
| −12 | 0 (0) | 9 (1) | .6 | 0 (0) | 8 (1) | > .99 | ||||
| −13 | 0 (0) | 8 (1) | .6 | 0 (0) | 6 (1) | > .99 | ||||
| −17 | 1 (1) | 14 (2) | > .99 | 0 (0) | 10 (2) | > .99 | ||||
| −18 | 0 (0) | 14 (2) | .4 | 0 (0) | 10 (2) | > .99 | ||||
| −20 | 0 (0) | 6 (1) | > .99 | 0 (0) | 2 (< 0.5) | > .99 | ||||
| −X | 0 (0) | 19 (2) | .15 | 0 (0) | 12 (2) | > .99 | ||||
| −Y | 2 (2) | 37 (6) | .3 | 1 (3) | 23 (4) | > .99 | ||||
| −X/Y | 2 (2) | 56 (7) | .04 | 1 (3) | 35 (6) | > .99 | ||||
| +4 | 2 (2) | 6 (1) | .2 | 0 (0) | 5 (1) | > .99 | ||||
| +6 | 1 (1) | 9 (1) | > .99 | 0 (0) | 5 (1) | > .99 | ||||
| +8 | 14 (13) | 69 (8) | .2 | 2 (6) | 63 (11) | .6 | ||||
| +11 | 1 (1) | 11 (1) | > .99 | 0 (0) | 4 (1) | > .99 | ||||
| +13 | 1 (1) | 9 (1) | > .99 | 1 (3) | 8 (1) | .4 | ||||
| +19 | 0 (0) | 6 (1) | > .99 | 0 (0) | 4 (1) | > .99 | ||||
| +21 | 2 (2) | 18 (2) | > .99 | 2 (6) | 13 (2) | .18 | ||||
| +22 | 3 (3) | 15 (2) | .5 | 2 (6) | 11 (2) | .14 | ||||
| t(6; 9) | 1 (1) | 4 (< 0.5) | .5 | 0 (0) | 4 (1) | > .99 | ||||
| t(9; 11) | 1 (1) | 1 (< 0.5) | .2 | 0 (0) | 1 (< 0.5) | > .99 | ||||
| t(9; 22) | 0 (0) | 9 (1) | .6 | 0 (0) | 5 (1) | > .99 | ||||
| t(10; 11) | 4 (4) | 9 (1) | .06 | 0 (0) | 9 (2) | > .99 | ||||
| t(11; 19) | 0 (0) | 4 (< 0.5) | > .99 | 1 (3) | 2 (< 0.5) | .15 | ||||
| t(11 q23) | 0 (0) | 11 (1) | .4 | 0 (0) | 6 (1) | > .99 | ||||
| abn(11p15) | 1 (1) | 5 (1) | .5 | 0 (0) | 1 (< 0.5) | > .99 | ||||
| abn(12p13) | 1 (1) | 8 (1) | > .99 | 0 (0) | 6 (1) | > .99 | ||||
| abn(8p 11) | 1 (1) | 2 (< 0.5) | .3 | 0 (0) | 2 (< 0.5) | > .99 | ||||
| Adverse | ||||||||||
| Complex | 2 (2) | 52 (6) | .08 | 1 (3) | 38 (7) | .7 | ||||
| −5 | 1 (1) | 18 (2) | .7 | 0 (0) | 13 (2) | > .99 | ||||
| del(5q) | 0 (0) | 21 (3) | .16 | 0 (0) | 16 (3) | > .99 | ||||
| −7 | 3 (3) | 33 (4) | .8 | 2 (6) | 24 (4) | .6 | ||||
| abn(3q) | 1 (1) | 12 (1) | .8 | 0 (0) | 10 (2) | > .99 | ||||
| inv(3) | 2 (2) | 9 (1) | .6 | 1 (3) | 9 (2) | .4 | ||||
| t(3; 5) | 5 (5) | 3 (< 0.5) | .001† | 0 (0) | 6 (1) | > .99 | ||||
. | NRAS . | . | . | KRAS . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cytogenetic subgroup . | Mutant, no. (%) . | Nonmutant, no. (%) . | P . | Mutant, no. (%) . | Nonmutant, no. (%) . | P . | ||||
| No data | 17 | 167 | .3 | 8 | 131 | .8 | ||||
| Cytogenetics available | 109 | 813 | 31 | 569 | ||||||
| Favorable | ||||||||||
| t(15; 17) | 8 (7) | 138 (17) | .008* | 5 (16) | 109 (19) | .8 | ||||
| t(8; 21) | 5 (5) | 82 (10) | .07 | 3 (10) | 56 (10) | > .99 | ||||
| inv(16) | 11 (10) | 49 (6) | .14 | 7 (23) | 35 (6) | .004† | ||||
| Intermediate | ||||||||||
| Normal | 48 (44) | 292 (36) | .11 | 7 (23) | 191 (34) | .2 | ||||
| abn(11q) | 1 (1) | 11 (1) | > .99 | 1 (3) | 8 (1) | .3 | ||||
| abn(12p) | 1 (1) | 11 (1) | > .99 | 1 (3) | 7 (1) | .3 | ||||
| abn(15q) | 1 (1) | 5 (1) | .5 | 0 (0) | 5 (1) | > .99 | ||||
| abn(16q) | 1 (1) | 17 (2) | .7 | 2 (6) | 11 (2) | .14 | ||||
| abn(17p) | 1 (1) | 18 (2) | .7 | 0 (0) | 12 (2) | > .99 | ||||
| abn(1p) | 1 (1) | 14 (2) | > .99 | 1 (3) | 6 (1) | .3 | ||||
| abn(1q) | 2 (2) | 9 (1) | .6 | 1 (3) | 7 (1) | .3 | ||||
| abn(20q) | 0 (0) | 8 (1) | .6 | 0 (0) | 8 (1) | > .99 | ||||
| abn(21q) | 0 (0) | 8 (1) | .6 | 1 (3) | 3 (1) | .2 | ||||
| abn(6q) | 0 (0) | 9 (1) | .6 | 0 (0) | 5 (1) | > .99 | ||||
| abn(7p) | 1 (1) | 14 (2) | > .99 | 0 (0) | 10 (2) | > .99 | ||||
| add(5q) | 0 (0) | 5 (1) | > .99 | 0 (0) | 5 (1) | > .99 | ||||
| add(7q) | 0 (0) | 7 (1) | > .99 | 1 (3) | 6 (1) | .3 | ||||
| del(13q) | 0 (0) | 5 (1) | > .99 | 0 (0) | 2 (< 0.5) | > .99 | ||||
| del(7q) | 2 (2) | 23 (3) | .8 | 1 (3) | 19 (3) | > .99 | ||||
| del(9q) | 0 (0) | 18 (2) | .2 | 0 (0) | 10 (2) | > .99 | ||||
| i(8q) | 0 (0) | 3 (< 0.5) | > .99 | 0 (0) | 2 (< 0.5) | > .99 | ||||
| −3 | 0 (0) | 5 (1) | > .99 | 0 (0) | 5 (1) | > .99 | ||||
| −9 | 1 (1) | 2 (< 0.5) | .3 | 0 (0) | 3 (1) | > .99 | ||||
| −12 | 0 (0) | 9 (1) | .6 | 0 (0) | 8 (1) | > .99 | ||||
| −13 | 0 (0) | 8 (1) | .6 | 0 (0) | 6 (1) | > .99 | ||||
| −17 | 1 (1) | 14 (2) | > .99 | 0 (0) | 10 (2) | > .99 | ||||
| −18 | 0 (0) | 14 (2) | .4 | 0 (0) | 10 (2) | > .99 | ||||
| −20 | 0 (0) | 6 (1) | > .99 | 0 (0) | 2 (< 0.5) | > .99 | ||||
| −X | 0 (0) | 19 (2) | .15 | 0 (0) | 12 (2) | > .99 | ||||
| −Y | 2 (2) | 37 (6) | .3 | 1 (3) | 23 (4) | > .99 | ||||
| −X/Y | 2 (2) | 56 (7) | .04 | 1 (3) | 35 (6) | > .99 | ||||
| +4 | 2 (2) | 6 (1) | .2 | 0 (0) | 5 (1) | > .99 | ||||
| +6 | 1 (1) | 9 (1) | > .99 | 0 (0) | 5 (1) | > .99 | ||||
| +8 | 14 (13) | 69 (8) | .2 | 2 (6) | 63 (11) | .6 | ||||
| +11 | 1 (1) | 11 (1) | > .99 | 0 (0) | 4 (1) | > .99 | ||||
| +13 | 1 (1) | 9 (1) | > .99 | 1 (3) | 8 (1) | .4 | ||||
| +19 | 0 (0) | 6 (1) | > .99 | 0 (0) | 4 (1) | > .99 | ||||
| +21 | 2 (2) | 18 (2) | > .99 | 2 (6) | 13 (2) | .18 | ||||
| +22 | 3 (3) | 15 (2) | .5 | 2 (6) | 11 (2) | .14 | ||||
| t(6; 9) | 1 (1) | 4 (< 0.5) | .5 | 0 (0) | 4 (1) | > .99 | ||||
| t(9; 11) | 1 (1) | 1 (< 0.5) | .2 | 0 (0) | 1 (< 0.5) | > .99 | ||||
| t(9; 22) | 0 (0) | 9 (1) | .6 | 0 (0) | 5 (1) | > .99 | ||||
| t(10; 11) | 4 (4) | 9 (1) | .06 | 0 (0) | 9 (2) | > .99 | ||||
| t(11; 19) | 0 (0) | 4 (< 0.5) | > .99 | 1 (3) | 2 (< 0.5) | .15 | ||||
| t(11 q23) | 0 (0) | 11 (1) | .4 | 0 (0) | 6 (1) | > .99 | ||||
| abn(11p15) | 1 (1) | 5 (1) | .5 | 0 (0) | 1 (< 0.5) | > .99 | ||||
| abn(12p13) | 1 (1) | 8 (1) | > .99 | 0 (0) | 6 (1) | > .99 | ||||
| abn(8p 11) | 1 (1) | 2 (< 0.5) | .3 | 0 (0) | 2 (< 0.5) | > .99 | ||||
| Adverse | ||||||||||
| Complex | 2 (2) | 52 (6) | .08 | 1 (3) | 38 (7) | .7 | ||||
| −5 | 1 (1) | 18 (2) | .7 | 0 (0) | 13 (2) | > .99 | ||||
| del(5q) | 0 (0) | 21 (3) | .16 | 0 (0) | 16 (3) | > .99 | ||||
| −7 | 3 (3) | 33 (4) | .8 | 2 (6) | 24 (4) | .6 | ||||
| abn(3q) | 1 (1) | 12 (1) | .8 | 0 (0) | 10 (2) | > .99 | ||||
| inv(3) | 2 (2) | 9 (1) | .6 | 1 (3) | 9 (2) | .4 | ||||
| t(3; 5) | 5 (5) | 3 (< 0.5) | .001† | 0 (0) | 6 (1) | > .99 | ||||
Patients with more than one cytogenetic abnormality will appear in more than one subgroup; therefore, total numbers in columns add up to more than the total number of patients. Percentages (in parentheses) are of total number of cases with available cytogenetic data. abn indicates abnormalities involving.
Significant underrepresentation of RAS mutation.
Significant overrepresentation of RAS mutation.